WORK Medical Technology Group LTD (Class A) (WOK) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $1.00 (0.00% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, WOK ranks #256 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while NVNO leads on capital efficiency (-35.0% ROIC).
Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $13.9M in revenue (-68.0% YoY), -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 35.3% FCF Margin ($4.9M FCF) & 52% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While WOK currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.66) and Max Pain ($1.05) forces dealer call-delta covering toward $87,780.00.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
WORK Medical Technology Group LTD (Class A) (WOK) slipped 0.00% to $1.00, trading at 2% of its 52-week range ($1 – $83600). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
Auckland, New Zealand, June 16, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, today announced that it will effect a re
Hangzhou, China, June 03, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China today announced the establishment of its
Deepening Engagement with the Global Biopharmaceutical Community Auckland, New Zealand, June 05, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplie
Yahoo Finance coverage on WOK stock catalysts, institutional flow, and earnings outlook.
Hangzhou, China, May 01, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) M
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -68.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on WOK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for WOK. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, WORK Medical Technology Group LTD (Class A) (WOK) ranks #256 by composite RQD confidence (51/100, grade D) and #953 by equity capitalization ($4.5M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while NVNO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. WOK currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| WOK
ACTIVE
WORK Medical Technology Group LTD (Class A) | D | 51/100 | — | — | — | 0.00% | $4.5M | Benchmark Subject |
| NVNO enVVeno Medical Corporation | E | 33/100 | — | — | -35.0% | +2.08% | $4.7M | /nvno-vs-wok → |
| SNOA Sonoma Pharmaceuticals Inc. | E | 34/100 | — | 38.0% | -35.0% | 0.00% | $5.3M | /snoa-vs-wok → |
| XAIR Beyond Air Inc. | E | 30/100 | 112.1x | 3.3% | -35.0% | -1.34% | $3.7M | /xair-vs-wok → |
| TNON Tenon Medical Inc. | E | 30/100 | — | 59.8% | -35.0% | -5.85% | $5.5M | /tnon-vs-wok → |
In its most recent audited fiscal period (FY2025, filed 2025-09-30), WORK Medical Technology Group LTD (Class A) (WOK) reported GAAP revenue of $13.9M (-68.0% vs. FY2024 revenue of $43.5M , and +65.8% cumulative change since FY2023) , GAAP net income of -$1.1M, operating cash flow of $6.2M, and free cash flow of $4.9M (+142.9% YoY). On the balance sheet, WOK closed FY2025 with $33.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $13.9M | -$1.1M | $6.2M | $4.9M | $33.2M | — |
| FY2024 (FY) | 2024-09-30 | $43.5M | -$3.5M | -$2.2M | -$11.5M | — | — |
| FY2023 (FY) | 2023-09-30 | $8.4M | $112.0K | $2.2M | $2.2M | — | — |
As of 2026-11-03, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $1.00 (0.00% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, WOK ranks #256 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while NVNO leads on capital efficiency (-35.0% ROIC).
Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $13.9M in revenue (-68.0% YoY), -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
WOK last traded at $1.00 (0.00% on volume of 31,974 shares), positioning the stock -39.76% below its 50-day simple moving average ($1.66) and -98.36% below its 200-day simple moving average ($60.94). Across its 52-week range of $1.00 to $83,600.00, WOK sits at the 0.0% percentile with a 14-day RSI of 31.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.13).
WORK Medical Technology Group LTD (Class A) (WOK) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.00 (0.00% 1D, market capitalization $4.5M).
WORK Medical Technology Group LTD (Class A) is a NASDAQ-listed issuer classified in the Health Care sector and the Medical/Dental Instruments industry.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), WORK Medical Technology Group LTD (Class A) (WOK) reported $13.9M in annual revenue (up from $43.5M in FY2024, -68.0% YoY) and -$1.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.4M revenue, $112.0K net income) through FY2025, WOK scaled operating cash flow to $6.2M and free cash flow to $4.9M, backed by $33.2M in total assets against $0 in total debt.
The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated names for WOK.
Real-time company headlines, analyst actions, and sector developments for WORK Medical Technology Group LTD (Class A) (WOK) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering WORK Medical Technology Group LTD (Class A) (WOK) market action, institutional positioning, and fundamental catalysts.
Auckland, New Zealand, June 16, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, today announced that it will effect a re
Hangzhou, China, June 03, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China today announced the establishment of its
Deepening Engagement with the Global Biopharmaceutical Community Auckland, New Zealand, June 05, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplie
Don't sleep on WOK's setup in Health Care. Balance-sheet pillar scores 13/20 with Altman Z of 2.5 and Debt/Equity of 0.5, and FY 2025 FCF of $4.9M was positive after a prior-year deficit.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (51/100) backs up the fundamental quality.
Both sides have a point here — WOK's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Here is the bear case nobody on the bull side wants to address on WOK: ROIC and FCF yield are both 0% and reported revenue is $0.0M in every period, while whale 13F flow scores only 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: